RareCan, a new company accelerating research into rare cancers, has appointed Dr Anita Cooper as Non-Executive Director. The appointment is said to strengthen the scientific and pharmaceutical experience of RareCan’s board in support of the company’s planned commercial growth.
With over 30 years’ global business experience, Cooper has worked across diverse functions, skill levels and geographies, including strategy development and implementation, risk management, operations and technology-enabled process transformation across the US, Latin America, Europe, India, Japan, South Korea, Taiwan and China. She is currently a Non-Executive Director for Simbec-Orion, a Clinical Research Organisation with specialist expertise in clinical pharmacology, oncology and rare diseases. Prior to this, she served as an Executive Officer and Senior Vice-President of Parexel, a US based, global pharmaceutical services company.
Piers Kotting, CEO of RareCan, commented: “We are thrilled to welcome Anita to the Board of RareCan. Anita’s wealth of industry experience will help us to accelerate rare cancer research by maximising the value of RareCan to both the global life sciences and pharmaceutical services industries.”
Cooper’s appointment follows the news that RareCan has been shortlisted for Start Up Entrepreneur of the Year at the 2021 Great British Entrepreneur Awards for the NorthEast region. The awards celebrate and champion the entrepreneurs behind brilliant businesses. Winners will be announced in September.
